Abbott Laboratories (NYSE:ABT) declared that its clinical trial of Tecnis Symfony 1-Piece Acrylic Intraocular Lens (IOL) fulfilled its main objective of enhanced intermediate vision.
Data from this trial demonstrated that people who got the Tecnis Symfony lens achieved considerably enhanced intermediate and near vision benchmarked against those who got a monofocal IOL. Jason Jones, M.D. of Jones Eye Clinic, Sioux City, Iowa presented the data today in New Orleans at the American Society of Cataract and Refractive Surgery (ASCRS).
Several patients with cataracts are demanding an option that will assist them with activities such as reading, utilize their computers at intermediate distance and view things that are at a far distance. The data from this trial revealed that patients who got the Symfony lens were more able to attain enhanced intermediate as well as near vision while retaining similar distance vision compared with subjects who got a standard IOL.
A cataract is a disorder in which the lens within the eye is cloudy. Symptoms include poor night vision, cloudy vision, faded color patterns and frequent requirement to alter glasses prescription.
Cataract surgery is among the safest and most frequent surgeries done by eye surgeons. Annually nearly 4 million surgeries are done in America. That figure is anticipated to increase considerably with the aging of the population and as fresh lens options are debuted that give people more choices for enhancing their vision and retaining their active lifestyle subsequent to cataract surgery. Although frequent in older adults, the demographics of cataract patients are changing. In this year it was forecast that 900,000 cataract surgeries would be done in America on patients less than 65 years old.
Compared to monofocal IOLs that give a fixed focal point at one specific distance, the Tecnis Symfony has proprietary optical functionality designed to lengthen the range of the eye’s focus and deliver a continuous range of vision at distance, near and intermediate.
The Symfony IOL has been extensively evaluated with information from over 7 studies in more than 2,000 eyes gathered. It is approved for use in over 50 nations globally. However the Symfony IOL is under review in the US and not approved for commercial use yet.